These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6271048)

  • 21. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillin.
    Mason EO; Kaplan SL; Anderson DC; Hinds DB; Feigin RD
    Antimicrob Agents Chemother; 1980 Mar; 17(3):470-3. PubMed ID: 6448579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of gentamycin combined with beta-lactam antibiotics against penicillin-resistant and non-resistant Streptococcus agalactiae].
    Villar H; Jugo M; Farinati A
    Enferm Infecc Microbiol Clin; 1994 Oct; 12(8):385-9. PubMed ID: 7981289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
    Corrado ML; Landesman SH; Cherubin CE
    Antimicrob Agents Chemother; 1980 Dec; 18(6):893-6. PubMed ID: 6263178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
    Eickhoff TC; Ehret J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):435-42. PubMed ID: 6264845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First molecular characterization of group B streptococci with reduced penicillin susceptibility.
    Kimura K; Suzuki S; Wachino J; Kurokawa H; Yamane K; Shibata N; Nagano N; Kato H; Shibayama K; Arakawa Y
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2890-7. PubMed ID: 18490507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1995 Jun; 35(6):883-8. PubMed ID: 7559200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal studies of penicillin-gentamicin combinations against group B streptococci.
    Overturf GD; Horowitz M; Wilkins J; Leedom J; Steinberg E
    J Antibiot (Tokyo); 1977 Jun; 30(6):513-8. PubMed ID: 328471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonism of ampicillin and chloramphenicol for meningeal isolates of group B streptococci.
    Weeks JL; Mason EO; Baker CJ
    Antimicrob Agents Chemother; 1981 Sep; 20(3):281-5. PubMed ID: 7030197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.
    Baker CN; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1980 Apr; 17(4):757-61. PubMed ID: 6249195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of moxalactam (LY-127935) compared with cefotaxime and other beta-lactam antibiotics against clinical isolates of enterobacteriacea and non-fermenters.
    Verbist L
    Arzneimittelforschung; 1981; 31(6):982-6. PubMed ID: 6266430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
    Pusztai-Markos Z; Pranada F
    Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci.
    Baker CN; Thornsberry C; Facklam RR
    Antimicrob Agents Chemother; 1981 May; 19(5):716-25. PubMed ID: 7027921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High rate of slowly-killed-by-ampicillin phenotype among group B streptococci with reduced penicillin susceptibility.
    Taniguchi R; Kimura K; Miyazaki A; Banno H; Jin W; Yamada K; Wachino JI; Arakawa Y
    J Antimicrob Chemother; 2017 Mar; 72(3):941-942. PubMed ID: 27999012
    [No Abstract]   [Full Text] [Related]  

  • 36. Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.
    Yu PK; Edson RS; Washington JA; Hermans PE
    Antimicrob Agents Chemother; 1983 Jan; 23(1):179-81. PubMed ID: 6219619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility of group B streptococci to 16 beta-lactam antibiotics, including new penicillin and cephalosporin derivatives.
    Jacobs MR; Kelly F; Speck WT
    Antimicrob Agents Chemother; 1982 Nov; 22(5):897-900. PubMed ID: 6758692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Oct; 8(4):323-31. PubMed ID: 6271726
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.